Loading
A phase 2 trial of Dostarlimab and Carboplatin in endometrial cancer, run by GlaxoSmithKline, now recruiting.
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) is a phase 2 interventional study registered as NCT07108270 by GlaxoSmithKline, with 30 participants planned, started 2025-11-27 and due to reach its primary completion in 2030-03-31. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dostarlimab, GSK, Platinum agents, Carboplatin and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Platinum agents, Carboplatin and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares GSK, Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, GSK, Endometrial cancer and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/